Security Snapshot

HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) Institutional Ownership

Q: What is CUSIP 427746102?

CUSIP 427746102 is the security identifier used in SEC filing datasets for HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share.

Q: Who owns HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share based on 13F filings?

156 institutions reported positions in HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share as of Q1 2026. Open the latest holders period and ownership history tables on this page for position-level details.

CUSIP: 427746102

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

156

Shares (Excl. Options)

156,359,005

Price

$0.80

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Type / Class: Equity / Common Stock, par value $0.01 per share
Symbol: HRTX on Nasdaq
Shares outstanding: 182,615,507
Price per share: $1.19
All holders as of 31 Mar 2026: Q1 2026
Total 13F shares: 156,359,005
Total reported value: $125,100,695
% of total 13F portfolios: 0%
Share change: -78,438
Value change: -$7,284,081
Number of holders: 156
Price from insider filings: $1.19

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Quick Takeaways

HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share is tracked under CUSIP 427746102.
156 institutions reported positions in Q1 2026.
2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

Holder count moved from 169 to 156 between Q4 2025 and Q1 2026.
Reported value moved from $203,256,533 to $125,100,695.

Why This Matters

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 156 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 427746102?
CUSIP 427746102 identifies HRTX - HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Next ownership checks

Use the next link that matches the question you still need to answer about this security.

Latest 13F filings when you want to inspect fresh institutional portfolio moves.
Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
All institutional ownership pages to compare this security with other holder-history pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 427746102:

Q1 2026 (156 holders) Q4 2025 (169 holders) Q3 2025 (171 holders) Q2 2025 (170 holders) Q1 2025 (164 holders) Q4 2024 (161 holders) Q3 2024 (169 holders) Q2 2024 (189 holders) Q1 2024 (157 holders) Q4 2023 (149 holders)

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Rubric Capital Management LP	16%	-8.9%	$37,859,003	+$1,192,086	30,046,828	+3.3%	Rubric Capital Management LP	15 Oct 2025
Clearline Capital LP	6.7%	+28%	$18,108,154	+$3,733,614	12,235,239	+26%	Clearline Capital LP	31 Dec 2025

As of 31 Mar 2026, 156 institutional investors reported holding 156,359,005 shares of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX). This represents 86% of the company’s total 182,615,507 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
Rubric Capital Management LP	16%	30,046,828	0%	0.29%	$24,040,467
Clearline Capital LP	6.7%	12,235,239	0%	0.76%	$9,789,415
BlackRock, Inc.	5.5%	10,106,422	-1.1%	0%	$8,086,147
ORBIMED ADVISORS LLC	5.4%	9,816,940		0.18%	$7,854,534
Velan Capital Investment Management LP	4.8%	8,753,290	0%	4.4%	$7,003,507
VANGUARD CAPITAL MANAGEMENT LLC	4.3%	7,810,329	0%	0%	$6,248,263
MILLENNIUM MANAGEMENT LLC	4.2%	7,630,527	+6.4%	0%	$6,105,185
Tejara Capital Ltd	3.5%	6,336,755	+23%	1.7%	$5,070,038
TANG CAPITAL MANAGEMENT LLC	3.4%	6,250,000	0%	0.25%	$5,000,625
PALISADE CAPITAL MANAGEMENT, LP	3.4%	6,140,639	-2.9%	0.16%	$4,913,125
Congress Park Capital LLC	2.2%	4,032,737	+31%	0.99%	$3,226,593
GEODE CAPITAL MANAGEMENT, LLC	2.2%	4,010,087	-1.7%	0%	$3,209,437
STATE STREET CORP	2.1%	3,843,672	+1.7%	0%	$3,075,322
JW Asset Management, LLC	2.1%	3,751,073	+2.2%	1.2%	$3,001,234
Pale Fire Capital SE	1.5%	2,716,328	+85%	0.19%	$2,173,334
D. E. Shaw & Co., Inc.	1.4%	2,600,990	-13%	0%	$2,081,052
NEW YORK STATE COMMON RETIREMENT FUND	1.4%	2,576,716	0%	0%	$2,061,630
UBS Group AG	1.3%	2,285,883	+9.3%	0%	$1,828,706
RENAISSANCE TECHNOLOGIES LLC	0.94%	1,718,300	-10%	0%	$1,374,812
Richmond Brothers, Inc.	0.79%	1,436,705	+151%	0.77%	$1,149,508
Stonepine Capital Management, LLC	0.77%	1,402,191	+13%	0.99%	$1,121,893
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.75%	1,376,367	-2.8%	0%	$1,101,231
VANGUARD PORTFOLIO MANAGEMENT LLC	0.72%	1,309,312	0%	0%	$1,047,450
NORTHERN TRUST CORP	0.64%	1,172,525	+7.4%	0%	$938,137
VANGUARD FIDUCIARY TRUST CO	0.63%	1,152,714	0%	0%	$922,171

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2026 Q1	156,359,005	$125,100,695	-$7,284,081	$1,707,892	$899,466	$0.80	156
2025 Q4	156,361,963	$203,256,533	+$5,483,358	$30,290	$485,030	$1.30	169
2025 Q3	152,658,767	$192,362,843	+$22,498,799	$2,668,554	$25,326	$1.26	171
2025 Q2	131,463,843	$272,131,676	+$12,999,478	$56,097	$3,233,754	$2.07	170
2025 Q1	124,770,231	$274,489,898	+$21,979,195	$104,940	$1,864,060	$2.20	164
2024 Q4	114,941,581	$175,829,179	-$13,146,397	$49,362	$3,059,388	$1.53	161
2024 Q3	121,816,811	$242,421,216	-$29,164,536	$188,851	$159,996	$1.99	169
2024 Q2	129,609,461	$453,638,008	+$35,415,047	$516,950	$331,450	$3.50	189
2024 Q1	119,262,673	$330,361,469	+$19,698,437	$285,310	$417,162	$2.77	157
2023 Q4	112,451,511	$191,165,565	+$1,074,277	$133,960	$386,410	$1.70	149
2023 Q3	118,378,841	$121,934,068	+$19,982,956	$6,077	$11,639	$1.03	138
2023 Q2	98,652,577	$114,435,495	-$11,706,623	$58,580	$19,024	$1.16	143
2023 Q1	107,852,430	$162,855,915	-$15,688,602	$30,804	$12,382	$1.51	153
2022 Q4	115,831,665	$289,582,111	-$29,877,564	$124,250	$2,593,750	$2.50	175
2022 Q3	121,963,764	$514,346,608	+$45,998,596	$239,000	$507,000	$4.22	178
2022 Q2	115,204,514	$321,404,107	+$4,826,591	$187,000	$856,000	$2.79	160
2022 Q1	108,535,070	$620,478,626	-$95,435,236	$2,088,652	$7,110,100	$5.72	176
2021 Q4	117,646,567	$1,073,655,355	+$78,398,633	$9,833,518	$12,277,249	$9.13	192
2021 Q3	108,488,554	$1,160,926,758	+$41,634,303	$1,283,000	$2,208,000	$10.69	189
2021 Q2	103,864,409	$1,612,145,175	+$202,378,763	$3,163,000	$4,246,000	$15.52	182
2021 Q1	89,846,972	$1,456,395,898	-$11,223,795	$3,396,000	$14,408,000	$16.21	186
2020 Q4	90,262,699	$1,910,380,366	+$26,526,144	$988,000	$2,362,000	$21.16	180
2020 Q3	90,857,946	$1,346,585,988	+$33,105,054	$645,000	$333,000	$14.82	177
2020 Q2	88,614,685	$1,334,393,703	-$51,210,796	$4,339,000	$2,571,000	$14.71	185
2020 Q1	92,095,623	$1,081,183,715	-$131,875,186	$7,371,000	$3,363,000	$11.74	186
2019 Q4	99,047,059	$2,326,444,060	+$183,809,453	$3,806,000	$4,082,000	$23.50	194
2019 Q3	91,435,188	$1,691,767,958	-$43,730,310	$5,187,000	$6,977,000	$18.50	175
2019 Q2	93,875,302	$1,744,712,239	+$2,233,456	$6,179,000	$6,654,000	$18.59	170
2019 Q1	92,662,760	$2,264,521,795	+$28,820,026	$7,559,000	$43,909,000	$24.44	189
2018 Q4	91,350,119	$2,369,031,974	+$92,438,916	$3,566,000	$5,989,000	$25.94	169
2018 Q3	87,463,202	$2,768,171,136	+$131,977,881	$5,757,000	$19,334,000	$31.65	187
2018 Q2	77,152,541	$2,997,578,965	+$216,890,926	$88,982,000	$33,827,000	$38.85	192
2018 Q1	72,567,037	$2,001,875,074	+$342,791,800	$32,734,000	$36,506,000	$27.60	149
2017 Q4	60,500,377	$1,095,067,241	+$103,341,807	$2,416,000	$13,480,000	$18.10	120
2017 Q3	63,406,329	$1,024,008,242	-$88,424,754	$1,536,000	$10,975,000	$16.15	101
2017 Q2	69,617,065	$964,195,934	+$47,548,351	$1,017,000	$23,489,000	$13.85	102
2017 Q1	71,661,852	$1,074,958,781	+$337,458,954	$1,472,000	$1,260,000	$15.00	98
2016 Q4	52,666,446	$689,938,271	+$4,719,852	$7,670,000	$20,264,000	$13.10	94
2016 Q3	51,265,727	$883,246,939	+$71,930,213	$6,967,000	$11,736,000	$17.23	88
2016 Q2	46,993,886	$848,220,501	+$35,391,534	$3,429,000	$12,412,000	$18.05	90
2016 Q1	45,017,464	$854,951,019	-$8,625,778	$7,874,000	$12,121,000	$18.99	98
2015 Q4	45,438,610	$1,214,308,493	+$39,761,438	$2,415,000	$32,428,000	$26.70	103
2015 Q3	43,669,932	$1,064,954,183	+$173,790,187	$32,055,000	$102,594,000	$24.40	101
2015 Q2	36,118,773	$1,125,171,985	+$319,523,410	$2,225,000	$69,154,000	$31.16	86
2015 Q1	26,445,484	$384,782,059	+$31,452,121	$426,000	$12,094,000	$14.55	68
2014 Q4	24,573,735	$247,206,453	+$2,536,942		$851,000	$10.06	62
2014 Q3	24,229,222	$201,828,829	-$7,802,513			$8.33	56
2014 Q2	26,551,442	$327,060,299	+$69,901,807			$12.32	67
2014 Q1	20,801,929	$289,178,683	+$283,529,683			$13.91	39